TMB and Inflammatory Gene Expression Associated with Clinical Outcomes following Immunotherapy in Advanced Melanoma

Outcomes for patients with melanoma have improved over the past decade as a result of the development and FDA approval of immunotherapies targeting cytotoxic T lymphocyte antigen-4 (CTLA-4), programmed death-1 (PD-1), and programmed death ligand 1 (PD-L1). However, these therapies do not benefit all...

Descripción completa

Detalles Bibliográficos
Autores principales: Hodi, F. Stephen, Wolchok, Jedd D., Schadendorf, Dirk, Larkin, James, Long, Georgina V., Qian, Xiaozhong, Saci, Abdel, Young, Tina C., Srinivasan, Sujaya, Chang, Han, Tang, Hao, Wind-Rotolo, Megan, Rizzo, Jasmine I., Jackson, Donald G., Ascierto, Paolo A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9414280/
https://www.ncbi.nlm.nih.gov/pubmed/34389558
http://dx.doi.org/10.1158/2326-6066.CIR-20-0983

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9414280/
https://www.ncbi.nlm.nih.gov/pubmed/34389558
http://dx.doi.org/10.1158/2326-6066.CIR-20-0983

Ejemplares similares